SAN DIEGO (TheStreet) -- Amylin Pharmaceuticals(AMLN_) shares will suffer a major shellacking Wednesday after U.S. regulators denied approval of the company's diabetes drug Bydureon, citing the need for additional clinical studies.
via thestreet.com
SAN DIEGO (TheStreet) -- Amylin Pharmaceuticals(AMLN_) shares will suffer a major shellacking Wednesday after U.S. regulators denied approval of the company's diabetes drug Bydureon, citing the need for additional clinical studies.
